NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free AKBA Stock Alerts $1.37 +0.01 (+0.74%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$1.35▼$1.4150-Day Range$1.35▼$2.2452-Week Range$0.65▼$2.48Volume2.08 million shsAverage Volume4.32 million shsMarket Capitalization$286.84 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Akebia Therapeutics alerts: Email Address Akebia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside260.7% Upside$5.00 Price TargetShort InterestBearish6.40% of Shares Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$300,598 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.28) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.42 out of 5 starsMedical Sector244th out of 910 stocksPharmaceutical Preparations Industry98th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.40% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 32.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 55.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.35. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Akebia Therapeutics this week, compared to 2 articles on an average week.Search Interest61 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 205% compared to the previous 30 days.MarketBeat Follows56 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 460% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $300,598.00 in company stock.Percentage Held by InsidersOnly 3.84% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 33.92% of the stock of Akebia Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Akebia Therapeutics Stock (NASDAQ:AKBA)Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AKBA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKBA Stock News HeadlinesApril 3, 2024 | marketbeat.comAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentAkebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemiaApril 3, 2024 | marketbeat.comAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentAkebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.April 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 21, 2024 | americanbankingnews.comStockNews.com Upgrades Akebia Therapeutics (NASDAQ:AKBA) to "Buy"April 15, 2024 | americanbankingnews.comShort Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Grows By 32.3%March 29, 2024 | msn.comBiggest stock movers today: AMC, PLTR, RH, and moreMarch 28, 2024 | finance.yahoo.comFDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated AnemiaMarch 28, 2024 | msn.comAkebia stock jumps as FDA clears renal anemia therapyApril 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 28, 2024 | markets.businessinsider.comAkebia's Vafseo Tablets Approved By FDA For Anemia Treatment In Dialysis PatientsMarch 28, 2024 | bizjournals.comTwo years after initial rejection, Akebia’s anemia drug finally gets FDA approvalMarch 27, 2024 | reuters.comU.S. FDA approves Akebia's anemia drugMarch 27, 2024 | prnewswire.comAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisMarch 27, 2024 | finance.yahoo.comAkebia Awaits FDA Word On Second Crack At VadadustatMarch 17, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33March 16, 2024 | finance.yahoo.comAkebia Therapeutics Full Year 2023 Earnings: EPS Beats ExpectationsMarch 15, 2024 | markets.businessinsider.comBuy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial PositionMarch 15, 2024 | finance.yahoo.comUS Life & Non-Life Insurance Market Poised for Strong Growth: In-Depth Analysis UnveiledMarch 14, 2024 | investorplace.comAKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023March 14, 2024 | benzinga.comRecap: Akebia Therapeutics Q4 EarningsMarch 14, 2024 | finance.yahoo.comAkebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable QuarterMarch 14, 2024 | prnewswire.comAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 14, 2024 | markets.businessinsider.comAkebia Therapeutics earnings: here's what Wall Street expectsMarch 13, 2024 | benzinga.comEarnings Preview For Akebia TherapeuticsMarch 11, 2024 | finance.yahoo.comAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 11, 2024 | prnewswire.comAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 1, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/23/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees167Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+261.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,920,000.00 Net Margins-26.32% Pretax Margin-26.68% Return on EquityN/A Return on Assets-20.36% Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio1.03 Sales & Book Value Annual Sales$194.62 million Price / Sales1.49 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-8.66Miscellaneous Outstanding Shares209,370,000Free Float201,332,000Market Cap$289.98 million OptionableOptionable Beta0.79 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. John P. Butler MBA (Age 60)CEO, President, Interim Principal Financial Officer & Director Comp: $1.29MMr. Michel Dahan (Age 45)Senior VP & COO Comp: $734.73kMs. Nicole R. Hadas J.D. (Age 51)Senior VP, Chief Legal Officer & Secretary Comp: $687.38kDr. Steven Keith Burke M.D. (Age 63)Senior VP of Research & Development and Chief Medical Officer Comp: $766.57kMr. Richard C. Malabre (Age 63)Chief Accounting Officer Ms. Kimberly GarkoSenior VP & Chief Technical OfficerTracey VetterickVice President of Portfolio Strategy & Corporate AdministrationMercedes CarrascoDirector of Corporate CommunicationsMs. Meredith BowmanSenior VP & Chief People OfficerMs. Carolyn RucciSenior Vice President of Legal & General CounselMore ExecutivesKey CompetitorsErascaNASDAQ:ERASCorMedixNASDAQ:CRMDVerrica PharmaceuticalsNASDAQ:VRCAInozyme PharmaNASDAQ:INZYTerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInsiders & InstitutionsCompass Ion Advisors LLCBought 25,095 shares on 4/18/2024Ownership: 0.012%Cannon Global Investment Management LLCBought 28,000 shares on 4/17/2024Ownership: 0.013%John P ButlerSold 46,570 sharesTotal: $73,580.60 ($1.58/share)Michel DahanSold 8,661 sharesTotal: $13,684.38 ($1.58/share)Nicole R HadasSold 5,974 sharesTotal: $9,438.92 ($1.58/share)View All Insider TransactionsView All Institutional Transactions AKBA Stock Analysis - Frequently Asked Questions Should I buy or sell Akebia Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKBA shares. View AKBA analyst ratings or view top-rated stocks. What is Akebia Therapeutics' stock price target for 2024? 3 brokerages have issued 12-month price objectives for Akebia Therapeutics' shares. Their AKBA share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 260.7% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts. How have AKBA shares performed in 2024? Akebia Therapeutics' stock was trading at $1.24 at the beginning of the year. Since then, AKBA shares have increased by 11.8% and is now trading at $1.3861. View the best growth stocks for 2024 here. Are investors shorting Akebia Therapeutics? Akebia Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 13,400,000 shares, an increase of 32.3% from the March 15th total of 10,130,000 shares. Based on an average daily volume of 4,530,000 shares, the days-to-cover ratio is currently 3.0 days. View Akebia Therapeutics' Short Interest. When is Akebia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AKBA earnings forecast. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings data on Thursday, March, 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). The biopharmaceutical company earned $56.20 million during the quarter, compared to analysts' expectations of $55.64 million. During the same quarter last year, the firm earned ($0.04) earnings per share. What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Cannon Global Investment Management LLC (0.01%) and Compass Ion Advisors LLC (0.01%). Insiders that own company stock include David A Spellman, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKBA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest MetalsIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.